Comparing sphenopalatine block and BOTOX for chronic migraine relief
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
This study is testing whether a nerve block or BOTOX injections can help people with chronic migraines feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06974617 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness and safety of two treatments for chronic migraine: sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injections. Chronic migraine is characterized by headaches occurring 15 or more days per month, with specific criteria for migraine episodes. The study aims to determine which treatment provides better relief for patients suffering from this debilitating condition. Participants will be monitored for their response to each intervention over a defined period.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 who experience chronic migraines.
Not a fit: Patients with medication overuse headaches or those with bleeding disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from chronic migraines.
How similar studies have performed: Previous studies have shown promising results for both sphenopalatine blocks and BOTOX in treating chronic migraines, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and 65 years. * Both sexes. * Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta. Exclusion Criteria: * Patients with medication over use headache. * Bleeding disorders. * Abnormal neurological examination. * History of allergy to local anesthetics or BOTOX.
Where this trial is running
Cairo
- Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Mohamed E Abdel Fattah, MD
- Email: mohamed-elsaid@cu.edu.eg
- Phone: 00201284475792
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.